CISPLATIN, VINBLASTINE, AND BLEOMYCIN IN THE TREATMENT OF METASTATIC MELANOMA - A PHASE-II STUDY OF THE SOUTHEASTERN-CANCER-STUDY-GROUP

  • 1 January 1985
    • journal article
    • research article
    • Vol. 69  (7-8) , 821-824
Abstract
Fifty-one patients with metastatic melanoma were treated with cisplatin, vinblastine and bleomycin. Of the 50 evaluable patients, 11 (22%) achieved an objective response, including 3 complete (6%) and 8 partial (16%) responses. Four of the 11 responding patients had previously received dacarbazine; the remaining patients had received no prior chemotherapy. Responses were noted in cutaneous and lymph node sites as well as visceral metastases. However, with 1 exception, all responding patients with visceral involvement had lung metastases. Response durations were brief and toxicity was substantial. Nadir leukocyte counts < 0.5 .times. 109/L occurred in 28% of the patients. Debilitating neurotoxicity, primarily paralytic ileus and severe nausea and emesis were experienced by 24% of the patients. The combination of cisplatin, vinblastine and bleomycin is not sufficiently beneficial to warrant its use in metastatic melanoma.